MEDai Helps Medicare Part D Sponsors Adhere To CMS Medication Therapy Management Initiative

Main Category: Medicare / Medicaid / SCHIP
Also Included In: Medical Practice Management
Article Date: 20 May 2009 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

MEDai, Inc., headquartered in Orlando, FL, a leading provider of advanced solutions for healthcare that utilize award-winning predictive analytics, announced that its solutions are actively assisting Medicare Part D benefit sponsors with the Centers for Medicare & Medicaid Services mandate, calling all Medicare Part D to offer members a medication therapy management (MTM) program.

MEDai's solutions grant Part D benefit sponsors the ability to identify MTM members who meet client-specific requirements as well as stratify patients using CMS mandated rules. The user-friendly applications collect, analyze and report on data that facilitates sponsor adherence to this new initiative. Clients can specify participation criteria; analyze the necessary data; and produce patient encounter documentation, patient and provider communication, and reporting documents.

"MEDai continues to develop solutions that address immediate needs in the payor market," said Swati Abbott, president of MEDai. "Our solutions offer numerous advantages, including the ability for Part D benefit sponsors to modify or create guidelines to identify members for MTM program participation, monitor the medication compliance and gaps in therapy for those members, and deliver that information to the point-of-care or to a member's personal health record," she added.

About MEDai

MEDai, Inc. is a subsidiary of Elsevier, a world-leading publisher of scientific, technical and medical information products and services. For more than a decade, MEDai has been offering award-winning solutions for the improvement of healthcare delivery. Utilizing cutting-edge technology, payors and care management organizations are able to predict patients at risk, identify cost drivers for their high-risk population, forecast future health plan costs, evaluate patient patterns over time and improve outcomes.

Source: MEDai, Inc